These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25748335)

  • 1. Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study.
    Breva LP; Domingo JD; Martínez Beneito MÁ; Barberà JP
    Vaccine; 2015 Apr; 33(18):2183-8. PubMed ID: 25748335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
    Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
    Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal C conjugate age-dependant long-term loss of effectiveness.
    Garrido-Estepa M; Nuñez OG; León-Gómez I; Cano R; Herruzo R
    Vaccine; 2015 May; 33(19):2221-2227. PubMed ID: 25819711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme.
    Gonçalves P; Sáez-López E; Carneiro S; Simões MJ
    PLoS One; 2021; 16(4):e0250103. PubMed ID: 33857245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012.
    Caini S; Beck NS; Yacouba H; Maiga I; Chaibou I; Hinsa I; Adakal A; Issoufou A; Kim SH; Pezzoli L
    Vaccine; 2013 Mar; 31(12):1597-603. PubMed ID: 23337027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
    Tin Tin Htar M; Jackson S; Balmer P; Serra LC; Vyse A; Slack M; Riera-Montes M; Swerdlow DL; Findlow J
    BMC Public Health; 2020 Dec; 20(1):1890. PubMed ID: 33298015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.
    Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA;
    Clin Infect Dis; 2014 Nov; 59(9):1208-15. PubMed ID: 25069868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based seroprevalence of Neisseria meningitidis serogroup C capsular antibody before the introduction of conjugate vaccine, in Australia.
    Backhouse JL; Gidding HF; MacIntyre CR; McIntyre PB; Gilbert GL
    Vaccine; 2007 Jan; 25(7):1310-5. PubMed ID: 17069937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
    Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
    Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.
    Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME
    Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario.
    Gasparini R; Rizzetto R; Sasso T; Rizzitelli E; Manfredi P; Risso D; Gentile C; Ciofi degli Atti M; Panatto D
    Vaccine; 2009 May; 27(25-26):3435-8. PubMed ID: 19200821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome.
    Taylor B; Andrews N; Stowe J; Hamidi-Manesh L; Miller E
    Arch Dis Child; 2007 Oct; 92(10):887-9. PubMed ID: 17468130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.